Oseltamivir for treatment and prophylaxis of influenza infection
- 9 April 2009
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Drug Safety
- Vol. 8 (3), 357-371
- https://doi.org/10.1517/14740330902840519
Abstract
Background: Influenza infection is a global problem affecting millions of people worldwide, despite efficacious vaccines. Treatment and prophylaxis against influenza have been successful using antiviral medications such as adamantanes and neuraminidase inhibitors. Objective: To review the antiviral agents and specifically the neuraminidase inhibitor, oseltamivir, for use in treatment and prophylaxis of influenza infection. Methods: This review focuses on published literature regarding the clinical use of oseltamivir, as well as discussing emerging threats such as avian influenza, antiviral resistance, and strategies such as combination antiviral treatment to mitigate these threats. Results: Oseltamivir is effective in reducing symptom burden in those with influenza A or B infection, and is preventative against developing infection after exposure. Emergence of naturally occurring or post-treatment oseltamivir-resistant influenza as well as an avian influenza pandemic may limit its future use as a monotherapeutic antiviral treatment agent.Keywords
This publication has 101 references indexed in Scilit:
- Pharmacokinetics and Tolerability of Oseltamivir Combined with ProbenecidAntimicrobial Agents and Chemotherapy, 2008
- InfluenzaCritical Care Medicine, 2008
- Current and future antiviral therapy of severe seasonal and avian influenzaAntiviral Research, 2008
- Antiviral Therapy and Outcomes of Influenza Requiring Hospitalization in Ontario, CanadaClinical Infectious Diseases, 2007
- A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivirCell Research, 2007
- WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virusThe Lancet Infectious Diseases, 2007
- Rapid Degradation of Oseltamivir Phosphate in Clinical Samples by Plasma EsterasesAntimicrobial Agents and Chemotherapy, 2006
- Molecular mechanisms of influenza virus resistance to neuraminidase inhibitorsVirus Research, 2004
- Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase InhibitorsClinical and Vaccine Immunology, 2004
- Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent InfluenzaNew England Journal of Medicine, 1999